MLH1 and neoplasm: The powerful Pol γ inhibitor identified in this study is CR that binds to the Pol γ enzyme with high affinity, specifically inhibits the activity of this enzyme, and can slow the in vivo growth of MLH1 deficient cancer cells and tumor xenografts in a synthetic lethal manner.